Biosimilars

Capping the price of reference drugs 'is detrimental' to biosimilars and generics, says the EGA

EGA: let originators charge more in Spain… to boost biosimilars

By Fiona BARRY

The European Generic and Biosimilar Medicines Association (EGA) and the Spanish Generic Medicines Association (AESEG) today revealed plans to remove market barriers to biosimilars and small molecule generics and create thousands of jobs.

Coming to America? Novartis subsidiary launches first biosimilar product in the US

Update - Wholesale cost of Zarxio will be 15% less than Amgen's Neupogen

Biosimilars land in the US as Sandoz launches Zarxio

By Dan Stanton

Sandoz has launched Zarxio, the first biosimilar in the US, despite a last ditch effort to block the copycat version of Neupogen by Amgen.

Celltrion manufactures a biosimilar to Janssen's Remicade

Celltrion presents data at US conference

By Gareth Macdonald

Celltrion’s Remsima campaign rolled into the US this week with another presentation of data showing that the Remicade (Infliximab) biosimilar is equivalent to the reference drug.

NJ Assembly committee approves biosimilar substitution bill

NJ Assembly committee approves biosimilar substitution bill

By Zachary Brennan

Under the bill first proposed in 2014, which won unanimous approval last week from a New Jersey Assembly committee, pharmacists would have to notify prescribers within five days of dispensing an interchangeable biosimilar.